Thank you for donating!

You can donate using the following services.

News

  1. 09.05.19

    Mallinckrodt - VTS-270-303 (9/5/19)

    An update from Mallinckrodt Pharmaceuticals regarding their study VTS-270-303...

    Read more
  2. 07.05.19

    NPUK News: Spring 2019

    We are happy to announce that the latest edition of NPUK News (Spring 2019) is here, full to the brim with everything our community needs - there's fundraising stories, events news, updates from staff and community members...and so much more!

    Read more
  3. 15.03.19

    CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol® Cyclo™ in Alzheimer’s Disease

    ALACHUA, FL – (Globe Newswire) – March 14, 2019 – CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer’s Disease. The trial will use Trappsol® Cyclo™, the company’s proprietary formulation of hydroxypropyl beta cyclodextrin, administered intravenously.

    Read more
  4. 11.03.19

    IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC)

    IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of Niemann-Pick Disease type C (NPC): OXFORD, UK, March 11, 2019-- IntraBio Inc., a late-stage biopharmaceutical company, today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved its Clinical Trial Authorisation (CTA) Application for Clinical Trial IB1001-201 with its lead compound (IB1001) for the treatment of Niemann-Pick disease Type C (NPC).

    Read more
  5. 01.03.19

    CTD Holdings Announces Grant to U.S. Non-Profit Organization to Support Patient Participation in Informational Meetings with Regulators

    Support is part of CTD’s efforts to recognize Rare Disease Day 2019...

    Read more